APA (7th ed.) Citation

Barco, S., Voci, D., Held, U., Sebastian, T., Bingisser, R., Colucci, G., . . . Kucher, N. (2022). Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): A randomised, open-label, parallel-group, multicentre, phase 3 trial. The lancet. Haematology, 9(8), . https://doi.org/10.1016/S2352-3026(22)00175-2

Chicago Style (17th ed.) Citation

Barco, Stefano, et al. "Enoxaparin for Primary Thromboprophylaxis in Symptomatic Outpatients with COVID-19 (OVID): A Randomised, Open-label, Parallel-group, Multicentre, Phase 3 Trial." The Lancet. Haematology 9, no. 8 (2022). https://doi.org/10.1016/S2352-3026(22)00175-2.

MLA (9th ed.) Citation

Barco, Stefano, et al. "Enoxaparin for Primary Thromboprophylaxis in Symptomatic Outpatients with COVID-19 (OVID): A Randomised, Open-label, Parallel-group, Multicentre, Phase 3 Trial." The Lancet. Haematology, vol. 9, no. 8, 2022, https://doi.org/10.1016/S2352-3026(22)00175-2.